Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

L.A. McKeown

September 18, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

Caitlin E. Cox

August 16, 2021

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Daily News

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Yael L. Maxwell

May 12, 2020

News Opinion CV Team Dispatch

April 2020 News Roundup

L.A. McKeown

April 10, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

Advertisement

August 2024 Dispatch for the CV Team

May 2024 Dispatch for the CV Team

AHA Selects 2023’s Leading Cardiovascular Research

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

October 2023 News Roundup

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

FDA Approves Two Additional Indications for Rivaroxaban in Children

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Roughly 80% of ESC Guideline Writers Have Financial COIs

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

April 2020 News Roundup

FDA Approves Two Generic Versions of Apixaban

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content